These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16456990)

  • 21. Merck accused of disguising its role in research.
    Cressey D
    Nature; 2008 Apr; 452(7189):791. PubMed ID: 18431823
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".
    Luepker RV
    Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016
    [No Abstract]   [Full Text] [Related]  

  • 23. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 24. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 25. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to 'Lapses at the NEJM'.
    Drazen JM
    J R Soc Med; 2006 Oct; 99(10):485; author reply 485. PubMed ID: 17021294
    [No Abstract]   [Full Text] [Related]  

  • 27. Merck withdraws Vioxx; FDA issues public health advisory.
    FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
    [No Abstract]   [Full Text] [Related]  

  • 28. Quebec allows Vioxx class-action suit.
    Sibbald B
    CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
    [No Abstract]   [Full Text] [Related]  

  • 29. Merck Sharpe and Dohme versus Laporte.
    Laporte JR
    Lancet; 2004 Jul 31-Aug 6; 364(9432):416. PubMed ID: 15288737
    [No Abstract]   [Full Text] [Related]  

  • 30. The New England Journal of Medicine: commercial conflict of interest and revisiting the Vioxx scandal.
    Wilson M
    Indian J Med Ethics; 2016; 1(3):167-71. PubMed ID: 27348431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Was Vioxx really that dangerous?
    Park A
    Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
    [No Abstract]   [Full Text] [Related]  

  • 32. Vioxx award good news for Canadian lawsuits.
    Eggertson L
    CMAJ; 2005 Sep; 173(7):744. PubMed ID: 16186576
    [No Abstract]   [Full Text] [Related]  

  • 33. Merck cleared in personal injury case against Vioxx.
    Mayor S
    BMJ; 2005 Nov; 331(7525):1101. PubMed ID: 16282390
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 35. Dispute over Vioxx study plays out in New England journal.
    Kondro W
    CMAJ; 2006 May; 174(10):1397. PubMed ID: 16682702
    [No Abstract]   [Full Text] [Related]  

  • 36. Vioxx risk could signify trouble in class.
    Frantz S
    Nat Rev Drug Discov; 2004 Nov; 3(11):899-901. PubMed ID: 15558856
    [No Abstract]   [Full Text] [Related]  

  • 37. The lessons of Vioxx.
    Frazier KC
    N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
    [No Abstract]   [Full Text] [Related]  

  • 38. NEJM "failed its readers" by delay in publishing its concerns about VIGOR trial.
    Dobson R
    BMJ; 2006 Jul; 333(7559):116. PubMed ID: 16840463
    [No Abstract]   [Full Text] [Related]  

  • 39. What's wrong with money in science.
    Stossel T; Shaywitz D
    Washington Post; 2006 Jul; ():B3. PubMed ID: 16838447
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads.
    Williams M
    Curr Opin Investig Drugs; 2005 Jan; 6(1):17-20. PubMed ID: 15675599
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.